(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 221.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.37%.
Precigen's revenue in 2026 is $9,684,000.On average, 5 Wall Street analysts forecast PGEN's revenue for 2026 to be $41,675,101,128, with the lowest PGEN revenue forecast at $30,973,713,801, and the highest PGEN revenue forecast at $53,514,015,206. On average, 5 Wall Street analysts forecast PGEN's revenue for 2027 to be $75,450,514,297, with the lowest PGEN revenue forecast at $53,899,797,459, and the highest PGEN revenue forecast at $95,136,027,034.
In 2028, PGEN is forecast to generate $115,458,611,380 in revenue, with the lowest revenue forecast at $110,931,863,665 and the highest revenue forecast at $118,852,787,344.